

WHAT'S NEXT FOR HIV VACCINES: From Design to Efficacy Testing

**SATELLITE SESSION
AT IAS 2015**



Satellite Session of IAS 2015

Sunday, July 19 | 5:00-7:00pm | Room 121-122

Refreshments will be served



© 2012 Benjamin Soro, Courtesy of Photoshare



Speakers and Panelists

- **Nina Russell**, Bill & Melinda Gates Foundation
- **Mary Marovich**, National Institute of Allergy and Infectious Diseases
- **William Schief**, The Scripps Research Institute and IAVI
- **Nelson Michael**, US Military HIV Research Program
- **Dan Barouch**, Beth Israel Deaconess Medical Center
- **Allan deCamp**, HIV Vaccine Trials Network
- **Frank Tomaka**, Janssen Pharmaceuticals

Organized by the Stakeholders of the Global HIV Vaccine Enterprise

- Bill & Melinda Gates Foundation
- HIV Vaccine Trials Network
- International AIDS Vaccine Initiative
- Institut national de la santé et de la recherche médicale
- US Military HIV Research Program
- National Institute of Allergy and Infectious Diseases

**BILL & MELINDA
GATES foundation**



The rapidly evolving field of HIV prevention research includes several promising strategies to prevent or treat HIV with a vaccine.

Please join us for an interactive session to explore the latest in HIV vaccine design, development and testing.

- What are the most promising, cross-platform approaches in development for preventive and therapeutic vaccines?
- Where are we in efforts to build on the success of the RV144 trial?
- What is the field learning from studies on novel immunogen design, unique vector platforms, mosaic antigen inserts and prime-boost vaccine regimens?
- What is the role of emerging strategies to administer broadly neutralizing antibodies by passive immunization?
- How do innovative efficacy trial designs optimize the evaluation of HIV vaccine candidates?